

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Single Technology Appraisal (STA)**

**Dapagliflozin in combination therapy for the treatment of type 2 diabetes**

**Matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bristol Myers Squibb and AstraZeneca (dapagliflozin)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black and Ethnic Minority Diabetes Association</li> <li>• Black Health Agency</li> <li>• Diabetes Research &amp; Wellness Foundation</li> <li>• Diabetes UK</li> <li>• Equalities National Council</li> <li>• Insulin Dependent Diabetes Trust</li> <li>• Insulin Pump Therapy (INPUT)</li> <li>• Insulin Pumpers UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Network of Sikh Organisations</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Surya Foundation</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for the Study of Obesity</li> <li>• Association of British Clinical Diabetologists</li> <li>• Association of Diabetes Specialist Nurses</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Society for Paediatric Endocrinology &amp; Diabetes</li> <li>• Diabetes Monitoring Forum</li> <li>• Diabetes Specialist Nurses</li> <li>• National Diabetes Nurse Consultant</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Diabetes UK Cymru</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (glipizide, metformin, tolbutamide)</li> <li>• Almus Pharmaceuticals (metformin, tolbutamide)</li> <li>• Aurobindo Pharma (glipizide, metformin)</li> <li>• Boehringer Ingelheim and Lilly Uk (linagliptin)</li> <li>• Bristol laboratories (metformin)</li> <li>• Bristol Myers Squibb, AstraZeneca (saxagliptin)</li> <li>• Eli Lilly (exenatide, insulin)</li> <li>• Goldshield (metformin)</li> <li>• Kent Pharmaceuticals (glibenclamide, glimepiride, metformin, tolbutamide)</li> <li>• Merck Sharpe and Dohme</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<p>Group</p> <ul style="list-style-type: none"> <li>• National Pharmacy Association</li> <li>• Primary Care Diabetes Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society of Endocrinology</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Gloucestershire</li> <li>• NHS Middlesbrough</li> <li>• Welsh Government</li> </ul>	<p>(metformin, sitagliptin)</p> <ul style="list-style-type: none"> <li>• Mylan (glimepiride, glipizide, metformin, tolbutamide)</li> <li>• Novartis Pharmaceuticals UK (metformin, vildagliptin)</li> <li>• Novo Nordisk (insulin, liraglutide)</li> <li>• Pfizer (glipizide)</li> <li>• Sanofi Aventis (glimepiride, insulin)</li> <li>• Somex Pharma (glimepiride)</li> <li>• Takeda (metformin, pioglitazone)</li> <li>• Teva UK (glibenclamide, glimepiride, glipizide, metformin)</li> <li>• Tillomed Laboratories (metformin)</li> <li>• Winthrop Pharmaceuticals UK (glimepiride, metformin)</li> <li>• Wockhardt UK (glibenclamide, insulin, metformin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• Diabetes Foundation</li> <li>• Heart Disease and Diabetes Research Trust</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• Warwick Evidence</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.